<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Skin abscesses in adults: Treatment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Skin abscesses in adults: Treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Skin abscesses in adults: Treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Denis Spelman, MBBS, FRACP, FRCPA, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Larry M Baddour, MD, FIDSA, FAHA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sandra Nelson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1303972168"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with skin and soft tissue infections may present with cellulitis, skin abscess, and other forms of infection [<a href="#rid1">1-3</a>].</p><p>This topic will discuss treatment of skin abscesses, including large furuncles and carbuncles. <span class="utd-adt-cnt utd-adt-pathwys utd-content-120460">(Related Pathway(s):  <a class="utd-content-120460" href="/pathway/120460?topicRef=138447&amp;source=see_link">Cellulitis and skin abscesses: Empiric antibiotic selection for adults</a>.)</span></p><p>Clinical manifestations and diagnosis of skin abscesses, furuncles, and carbuncles are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Skin abscess'</a> and  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p>Management of other forms of purulent skin infection, such as folliculitis and purulent cellulitis (cellulitis with purulent drainage or exudate without abscess), is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/110530.html" rel="external">"Acute cellulitis and erysipelas in adults: Treatment"</a>.)</p><p class="headingAnchor" id="H2672442723"><span class="h1">INCISION AND DRAINAGE</span><span class="headingEndMark"> — </span>To optimize the likelihood of cure, we recommend that all patients with a fluctuant skin abscess undergo incision and drainage to evacuate pus and necrotic debris [<a href="#rid4">4,5</a>]. In patients with small abscesses (&lt;2 cm) that are spontaneously draining, close observation is an acceptable alternative. If incision and drainage is not performed, we suggest that patients apply warm compresses to the infected area several times per day to promote drainage.</p><p>Extensive description of the technique for incision and drainage is found elsewhere (see  <a class="medical medical_review" href="/z/d/html/6336.html" rel="external">"Techniques for skin abscess drainage"</a>). During the incision and drainage procedure, we recommend that samples of pus be obtained and sent for Gram stain and culture.</p><p>Although it is less invasive, needle aspiration of abscess contents is not recommended [<a href="#rid2">2</a>]. An unblinded randomized trial of 101 patients with uncomplicated skin abscesses found that 32 of 43 individuals who underwent ultrasound-guided needle aspiration (74 percent) experienced clinical or ultrasonographic failure versus 10 of 49 who underwent incision and drainage (20 percent; difference 54 percentage points; 95% CI 35-69 percent). Appropriate antibiotics were given to the majority of individuals in both groups (92 percent and 93 percent, respectively) [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H1241910276"><span class="h1">ANTIMICROBIAL THERAPY</span></p><p class="headingAnchor" id="H126296845"><span class="h2">Indications for antimicrobial therapy</span><span class="headingEndMark"> — </span>We suggest antibiotic treatment for all patients undergoing incision and drainage of a skin abscess.</p><p>However, many abscesses are treated successfully with incision and drainage alone and expert opinion varies. For patients with multiple antibiotic allergies or intolerances or who prefer to forego antibiotic therapy, it is reasonable to withhold antibiotic therapy if the patient is otherwise healthy and meets all of the following criteria [<a href="#rid7">7-9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Single abscess.</p><p class="bulletIndent1"><span class="glyph">●</span>Size of abscess &lt;2 cm in diameter [<a href="#rid10">10-12</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>No or minimal surrounding cellulitis.</p><p class="bulletIndent1"><span class="glyph">●</span>No systemic signs of toxicity (eg, fever &gt;100.5°F/38°C, hypotension, or sustained tachycardia).</p><p class="bulletIndent1"><span class="glyph">●</span>No immunosuppression or other comorbidities.</p><p class="bulletIndent1"><span class="glyph">●</span>No prior clinical failure with incision and drainage alone.</p><p class="bulletIndent1"><span class="glyph">●</span>No indwelling medical device (such as prosthetic joint, vascular graft, or pacemaker).</p><p class="bulletIndent1"><span class="glyph">●</span>No risk factors for endocarditis – Risk factors for endocarditis are discussed below. (See <a class="local">'Increased risk of endocarditis'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>No exposure to situations that could increase transmission to others (eg, contact sports, military barracks).</p><p></p><p>Several trials have indicated a benefit to antibiotic therapy, even in patients with small abscesses [<a href="#rid10">10-14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Antibiotics decrease the likelihood of treatment failure. A meta-analysis of four randomized placebo-controlled trials involving more than 2400 patients with drained abscess found that the rate of treatment failure was 8 percent for patients who received antibiotics compared with 16 percent for those who received placebo (odds ratio [OR] for cure 2.3, 95% CI 1.8-3.1) [<a href="#rid13">13</a>]. Similar findings were found in another meta-analysis of 14 randomized trials involving more than 4000 patients who received either antibiotics or no antibiotics (OR for treatment failure with antibiotics 0.58, 95% CI 0.37-0.90) [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1">Antibiotics appear to improve outcomes regardless of lesion size, causative organism, or presence of fever or comorbidities based on a randomized placebo-controlled trial of 1220 patients with drained abscess who received <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> or placebo [<a href="#rid10">10,12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition to decreasing treatment failures, antimicrobial therapy decreases the risk of recurrent skin abscesses. One meta-analysis found that the recurrence rate within one month was 7.6 percent with antibiotics versus 14.5 percent without antibiotics (OR 0.48, 95% CI 0.30-0.77) and was 17.4 percent versus 25 percent after one month (OR 0.64, 95% CI 0.48-0.85) [<a href="#rid14">14</a>]. Another meta-analysis found that the rate of new lesions at 30 days of follow-up was lower in the group that received antibiotics compared with the group that received placebo (OR 0.32, 95% CI 0.2-0.4) [<a href="#rid13">13</a>].</p><p></p><p>Trials also indicate increased rates of adverse events in patients who receive antibiotics, but the large majority of adverse events in these trials were classified as mild, and the rate of adverse events was lower than the reported treatment benefits [<a href="#rid13">13,14</a>]. Gastrointestinal side effects are the most commonly reported adverse events in patients who receive antibiotics. In one meta-analysis, <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> was found to cause the highest rates of diarrhea when compared with no antibiotics (OR 2.71, 95% CI 1.50-4.89) [<a href="#rid14">14</a>].</p><p>Our recommendations differ from the 2014 Infectious Diseases Society of America guidelines on the management of skin and soft tissue infections, which do not recommend routine antibiotic therapy for patients with mild skin abscesses in the absence of systemic infection, immunocompromising conditions, extremes of age, or multiple abscesses [<a href="#rid2">2</a>]. The 2014 guidelines were published before the above trials and meta-analyses were published and were based on earlier smaller studies, some of which were performed before community-acquired methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) became the primary cause of skin abscesses [<a href="#rid9">9,15-18</a>].</p><p class="headingAnchor" id="H2330406154"><span class="h2">Timing of antimicrobial administration</span><span class="headingEndMark"> — </span>For most patients, we suggest withholding antimicrobial therapy until after samples for culture have been obtained to optimize culture results.</p><p>However, for certain patients, we suggest that antimicrobials be administered prior to incision and drainage:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients whose incision and drainage cannot be performed promptly</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who have an indication for parenteral therapy</strong> – These patients generally have more severe or rapidly progressive illness, and delaying antimicrobial therapy can be associated with worse outcomes, especially for patients with sepsis [<a href="#rid19">19-23</a>]. Indications for parenteral therapy are discussed below. (See <a class="local">'Indications for parenteral therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with risk factors for endocarditis</strong> – We suggest preprocedural antibiotics for these patients given the potential risk of transient bacteremia during the procedure and consequent seeding of a heart valve. Risk factors that warrant preprocedural antibiotics include a history of infective endocarditis, presence of a prosthetic valve or prosthetic perivalvular material, an unrepaired congenital heart defect, or valvular dysfunction in a transplanted heart. (See  <a class="medical medical_review" href="/z/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a>.)</p><p></p><p class="bulletIndent1">The specific timing of antibiotic administration prior to incision varies by antibiotic and is discussed below. (See <a class="local">'Increased risk of endocarditis'</a> below.) </p><p></p><p class="headingAnchor" id="H1802502154"><span class="h2">Antimicrobial selection</span><span class="headingEndMark"> — </span>The choice of antibiotic is typically dependent on the suspected microorganisms, severity of illness, and patient comorbidities  (<a class="graphic graphic_algorithm graphicRef139108" href="/z/d/graphic/139108.html" rel="external">algorithm 1</a>). <span class="utd-adt-cnt utd-adt-pathwys utd-content-120460">(Related Pathway(s):  <a class="utd-content-120460" href="/pathway/120460?topicRef=138447&amp;source=see_link">Cellulitis and skin abscesses: Empiric antibiotic selection for adults</a>.)</span></p><p class="headingAnchor" id="H3837851378"><span class="h3">Spectrum of empiric antimicrobial coverage</span><span class="headingEndMark"> — </span>Patients with skin abscess should receive empiric therapy that covers <em>S. aureus</em>, including MRSA [<a href="#rid1">1,2</a>]. Empiric therapy for infection due to beta-hemolytic streptococci (or uncommon pathogens, such as gram-negative bacilli) is generally not necessary, except in certain situations as discussed elsewhere. (See <a class="local">'Special populations'</a> below.)</p><p>This approach is supported by findings of a study including 422 patients with purulent soft tissue infection, 81 percent of whom had abscesses. Of 384 patients who had positive culture results, 320 (83 percent) grew <em>S. aureus</em>, of which 249 (78 percent) were MRSA. Beta-hemolytic streptococci accounted for a much smaller proportion of overall infections (2.6 percent) [<a href="#rid24">24</a>].</p><p>Further discussion of the microbiology of skin abscesses is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Skin abscess'</a>.)</p><p class="headingAnchor" id="H2675060206"><span class="h3">Indications for parenteral therapy</span><span class="headingEndMark"> — </span>The decision to initiate parenteral therapy is typically based on the extent and severity of infection and patient comorbidities. Patients who meet criteria for parenteral therapy are usually admitted to the hospital to ensure prompt administration and close observation.</p><p>For individuals with skin abscess, we suggest initial treatment with parenteral antibiotics in the following circumstances:</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic signs of toxicity (eg, fever &gt;100.5°F/38°C, hypotension, sustained tachycardia)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid progression of erythema or abscess</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extensive abscess or surrounding erythema</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompromising condition (eg, neutropenia, use of immunosuppressive drugs such as chemotherapy for malignancy)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inability to tolerate or absorb oral therapy</p><p></p><p class="headingAnchor" id="H625589955"><span class="h3">Preferred regimens</span></p><p class="headingAnchor" id="H4290213313"><span class="h4">Oral regimens</span><span class="headingEndMark"> — </span>Most individuals can be treated with oral antibiotics in the outpatient setting. For these patients, targeted empiric therapy that covers <em>S. aureus</em>, including MRSA, is appropriate. For most patients, we suggest one of the following empiric regimens  (<a class="graphic graphic_algorithm graphicRef139108" href="/z/d/graphic/139108.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> (one to two double-strength tablets orally twice daily; for patients who weigh more than 70 kg and have normal renal function, we favor two double-strength tablets twice daily)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">Doxycycline</a> (100 mg orally twice daily)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">Minocycline</a> (200 mg orally once, then 100 mg orally twice daily)</p><p></p><p><a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">Clindamycin</a> (450 mg orally every eight hours) is an acceptable alternative, but we generally avoid it due to risk for <em>Clostridioides difficile</em> infection and the possibility of staphylococcal resistance [<a href="#rid25">25-27</a>]. Local resistance rates should be reviewed before prescribing. Data from 2017 from the United States Centers for Disease Control and Prevention revealed that 47 percent of 471 invasive MRSA isolates were resistant to clindamycin [<a href="#rid28">28</a>].</p><p>In certain patient populations, we broaden coverage as described elsewhere. (See <a class="local">'Special populations'</a> below.)</p><p>Additional agents that should be reserved for when a preferred agent cannot be used are listed in the table  (<a class="graphic graphic_table graphicRef64178" href="/z/d/graphic/64178.html" rel="external">table 1</a>), and their efficacy is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3176.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections"</a>.)</p><p class="headingAnchor" id="H3868694361"><span class="h4">Parenteral regimens</span><span class="headingEndMark"> — </span>Parenteral antibiotic regimens are recommended for higher risk patients and are typically started prior to incision and drainage. (See <a class="local">'Indications for parenteral therapy'</a> above and <a class="local">'Timing of antimicrobial administration'</a> above.)</p><p>For most patients who warrant parenteral therapy, we suggest one of the following regimens  (<a class="graphic graphic_algorithm graphicRef139108" href="/z/d/graphic/139108.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> (refer to the table for dosing  (<a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">table 2</a>))</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> 4 to 6 mg/kg intravenously every 24 hours (alternative)</p><p></p><p>In certain patient populations, we broaden coverage as described elsewhere. (See <a class="local">'Special populations'</a> below.)</p><p><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> is the preferred option because of extensive experience with this agent. When <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> is used, we usually favor the higher dose (ie, 6 mg/kg). Additional agents that should be reserved for when a preferred agent cannot be used are listed in the table  (<a class="graphic graphic_table graphicRef110072" href="/z/d/graphic/110072.html" rel="external">table 3</a>), and their efficacy is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3176.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections"</a>.)</p><p>Once there is evidence of clinical improvement, parenteral antibiotics should be switched to one of the oral agents listed above.</p><p class="headingAnchor" id="H3276819910"><span class="h3">Special populations</span><span class="headingEndMark"> — </span>Patients with severe illness, certain comorbidities, or atypical locations of infection warrant altered management.</p><p class="headingAnchor" id="H2824844179"><span class="h4">Severe sepsis or an immunocompromising condition</span><span class="headingEndMark"> — </span>Patients with these conditions are at increased risk for mortality, so rapid institution of empiric parenteral broad-spectrum antibiotic coverage is indicated. Due to the urgency of antibiotic administration, we suggest administering antibiotics prior to incision and drainage as discussed above. (See <a class="local">'Timing of antimicrobial administration'</a> above.)</p><p>For empiric therapy for these patients, we use one of the regimens suggested for cellulitis in this patient-population  (<a class="graphic graphic_algorithm graphicRef139108" href="/z/d/graphic/139108.html" rel="external">algorithm 1</a>) (see  <a class="medical medical_review" href="/z/d/html/110530.html" rel="external">"Acute cellulitis and erysipelas in adults: Treatment", section on 'Patients with severe sepsis'</a>). If an organism is identified from culture, antibiotics should be narrowed to target the causative organism.</p><p>There is a spectrum of immunocompromising conditions such that it is difficult to describe a single unifying definition. Ultimately, the decision to use a broader spectrum regimen rather than a standard one requires clinical judgement and depends on the depth and type of immunosuppression.</p><p class="headingAnchor" id="H260190175"><span class="h4">Atypical abscess site (eg, perianal, breast, vulvar)</span><span class="headingEndMark"> — </span>Most skin abscesses occur on the extremities, back, or trunk. Skin abscesses in other anatomical sites (eg, perianal, breast, vulvar) often require an alteration of antibiotic selection or management. Management of these infections is discussed in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1378.html" rel="external">"Perianal and perirectal abscess", section on 'Management'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/795.html" rel="external">"Primary breast abscess", section on 'Treatment'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3312.html" rel="external">"Vulvar abscess", section on 'Management'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6079.html" rel="external">"Peritonsillar cellulitis and abscess"</a>.)</p><p></p><p class="headingAnchor" id="H2795542407"><span class="h4">Wound, injury, or medical device</span><span class="headingEndMark"> — </span>Management of abscesses associated with wounds or injury (eg, bites, pressure ulcers, diabetic wounds) or with underlying medical devices (eg, mesh, prosthetic joint, vascular graft) requires specific approaches, which are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7671.html" rel="external">"Animal bites (dogs, cats, and other mammals): Evaluation and management", section on 'Management'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7657.html" rel="external">"Infectious complications of pressure-induced skin and soft tissue injury", section on 'Management of soft tissue infection'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7651.html" rel="external">"Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities", section on 'Management'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15100.html" rel="external">"Wound infection following repair of abdominal wall hernia", section on 'Deep incisional surgical site/mesh infection'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7665.html" rel="external">"Prosthetic joint infection: Treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/120681.html" rel="external">"Overview of the evaluation and management of surgical site infection", section on 'Deep infection associated with implanted materials'</a>.)</p><p></p><p class="headingAnchor" id="H1973938251"><span class="h4">Increased risk of endocarditis</span><span class="headingEndMark"> — </span>We suggest preprocedural antibiotics for patients with risk factors for endocarditis. The specific risk factors that warrant preprocedural antibiotics are discussed above. (See <a class="local">'Timing of antimicrobial administration'</a> above.)</p><p></p><p>For such patients, we favor empirically covering beta-hemolytic <em>Streptococcus</em> in addition to MRSA because of the possibility (albeit small) of streptococcal involvement. All the oral and intravenous agents discussed above have been shown to be effective against streptococcal skin infections, except for the tetracyclines (eg, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>). When a <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> is used for these patients, we add <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> (875 mg orally twice daily) due to its reliable coverage of streptococci. (See <a class="local">'Oral regimens'</a> above and <a class="local">'Parenteral regimens'</a> above.)</p><p>The antibiotic regimen should be started 30 to 60 minutes prior to incision (administration of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> should begin 120 minutes before incision) [<a href="#rid29">29,30</a>]. (See  <a class="medical medical_review" href="/z/d/html/2147.html" rel="external">"Prevention of endocarditis: Antibiotic prophylaxis and other measures"</a>.)</p><p class="headingAnchor" id="H1694948660"><span class="h2">Duration of antimicrobial therapy</span><span class="headingEndMark"> — </span>The duration of therapy should be individualized based on clinical response. Patients are typically treated for five days; extension of the duration (up to 14 days) may be warranted in the setting of severe infection, slow response to therapy, or immunosuppression. Patients whose infection was complicated by staphylococcal bacteremia typically require more intensive and longer durations, as discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">"Clinical approach to Staphylococcus aureus bacteremia in adults", section on 'Management'</a>.)</p><p class="headingAnchor" id="H2662262860"><span class="h1">MONITORING RESPONSE</span><span class="headingEndMark"> — </span>Patients receiving outpatient therapy should have repeat evaluation 24 to 48 hours after treatment initiation to verify clinical response [<a href="#rid2">2</a>].</p><p>The goal of therapy is to achieve resolution of the abscess and surrounding cellulitis. Patients who undergo adequate incision and drainage typically have improvement in pain and size of the abscess shortly after the procedure. However, any surrounding cellulitis typically responds gradually; the natural evolution of resolving cellulitis is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/110530.html" rel="external">"Acute cellulitis and erysipelas in adults: Treatment", section on 'Monitoring response to therapy'</a>.)</p><p>It is useful to document the baseline appearance of the physical findings at the start of antibiotic therapy. We obtain a baseline digital photograph to help monitor progress. Some experts outline the area of infection with an indelible marker at the time of treatment initiation to allow objective monitoring of progress. Others do not outline the infection because patients sometimes experience unnecessary anxiety if the infection appears to extend beyond the line as the infection dissipates.</p><p class="headingAnchor" id="H2622948903"><span class="h1">REFRACTORY INFECTION</span><span class="headingEndMark"> — </span>Despite incision and drainage and a complete course of antibiotics, abscesses fail to resolve in about 10 percent of patients [<a href="#rid10">10,11</a>].</p><p>Failure to improve after incision and drainage and 24 to 48 hours of appropriate antibiotic therapy should prompt assessment for possible reasons for nonresponse.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inadequate drainage</strong> – This is one of the most common causes of treatment failure [<a href="#rid10">10,11</a>]. Evaluation should include imaging (eg, ultrasound) or re-exploration of the wound. In some cases, imaging may reveal the presence of a deeper, more serious infection than previously realized.</p><p></p><p>If residual abscess is not detected, other causes to be considered include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection with resistant organism</strong> – For patients in whom an initial culture was not obtained or was negative, sending a sample from the abscess cavity for Gram stain and culture should be performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inadequate dosing or tissue penetration of antibiotics</strong> – Certain conditions, such as obesity, limit penetration of antibiotics into sites of infection and may require higher dosages of antibiotics. Switching from oral to intravenous antibiotics can help in some cases as well. Further information regarding these issues can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/110530.html" rel="external">"Acute cellulitis and erysipelas in adults: Treatment", section on 'Refractory infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis other than skin abscess</strong> – Occasionally, skin abscess is confused with other infectious and noninfectious etiologies. The differential diagnosis of skin abscess is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Skin abscess'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inadequate adherence</strong> – A repeat course of antimicrobial therapy and wound care may be appropriate for patients with inadequate adherence to the treatment regimen.</p><p></p><p class="headingAnchor" id="H2947879865"><span class="h1">RECURRENT INFECTION</span><span class="headingEndMark"> — </span>Recurrences of skin abscesses are not uncommon, occurring in 7 to 14 percent of individuals within two months of completing therapy [<a href="#rid10">10,11</a>]. Although recurrences can occur at the original site of infection, they usually occur at locations other than the site of the initial abscess.</p><p class="headingAnchor" id="H1496917937"><span class="h2">Management of recurrent infections</span><span class="headingEndMark"> — </span>During the active stage of infection, management of recurrent skin abscess is the same as initial episodes. (See <a class="local">'Incision and drainage'</a> above and <a class="local">'Antimicrobial therapy'</a> above.)</p><p>If antibiotics were not used for the first episode, they should be used for subsequent episodes. Studies suggest that antimicrobial therapy decreases the risk of recurrent skin abscess, as described above. (See <a class="local">'Indications for antimicrobial therapy'</a> above.)</p><p>A recurrent abscess at a site of previous infection should prompt consideration of alternative etiologies such as pilonidal cyst, hidradenitis suppurativa, or presence of foreign material [<a href="#rid2">2</a>]. Surgical exploration and debridement may be warranted. (See  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Skin abscess'</a>.)</p><p>In adult patients whose abscesses began in early childhood, evaluation for neutrophil disorders should be performed. (See  <a class="medical medical_review" href="/z/d/html/3913.html" rel="external">"Primary disorders of phagocyte number and/or function: An overview"</a>.)</p><p class="headingAnchor" id="H3416342380"><span class="h2">Prevention of recurrences</span><span class="headingEndMark"> — </span>The mainstay of prevention includes attention to personal hygiene, decolonization, and consideration of the possibility of household or interpersonal transmission. These issues, including decolonization strategies, are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4048.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control", section on 'Decolonization'</a> and  <a class="medical medical_review" href="/z/d/html/6025.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in children: Prevention and control"</a>.)</p><p>There are little to no data to support the use of suppressive antibiotics to prevent recurrent skin abscesses [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H810371609"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110086.html" rel="external">"Society guideline links: Skin and soft tissue infections"</a>.)</p><p class="headingAnchor" id="H3363538142"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – This topic discusses treatment of skin abscesses, including large furuncles and carbuncles. Management of other forms of purulent skin infection, such as folliculitis and purulent cellulitis (cellulitis with purulent drainage or exudate without abscess), is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/110530.html" rel="external">"Acute cellulitis and erysipelas in adults: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incision and drainage</strong> – Fluctuant skin abscesses generally require incision and drainage to evacuate pus and necrotic debris  (<a class="graphic graphic_algorithm graphicRef139108" href="/z/d/graphic/139108.html" rel="external">algorithm 1</a>). Extensive description of the technique for incision and drainage is found elsewhere. (See <a class="local">'Incision and drainage'</a> above and  <a class="medical medical_review" href="/z/d/html/6336.html" rel="external">"Techniques for skin abscess drainage"</a>.)</p><p></p><p class="bulletIndent1">In patients with small abscesses (&lt;2 cm) that are spontaneously draining, close observation is an acceptable alternative.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for antimicrobial therapy</strong> – For all patients undergoing incision and drainage of a skin abscess, we suggest antibiotic therapy because it reduces the rate of treatment failure and recurrence (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). We feel most strongly about using antibiotics for those at highest risk (eg, multiple abscesses, abscess &gt;2 cm, extensive surrounding cellulitis, comorbidities or immunosuppression, signs of systemic infection, or inadequate clinical response to incision and drainage alone). However, because many abscesses can be treated successfully with incision and drainage alone, expert opinion varies, and it is reasonable to forgo antibiotic therapy in otherwise-healthy patients who have small (eg, &lt;2 cm) abscesses and no other comorbidities. (See <a class="local">'Indications for antimicrobial therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph utd-adt-cnt utd-adt-pathwys">●</span><strong>Antimicrobial selection</strong> – Empiric therapy should cover<em> Staphylococcus aureus</em>, including methicillin-resistant <em>S. aureus </em>(MRSA), which causes the vast majority of skin abscesses  (<a class="graphic graphic_algorithm graphicRef139108" href="/z/d/graphic/139108.html" rel="external">algorithm 1</a>). (See <a class="local">'Spectrum of empiric antimicrobial coverage'</a> above.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120460">(Related Pathway(s):  <a class="utd-content-120460" href="/pathway/120460?topicRef=138447&amp;source=see_link">Cellulitis and skin abscesses: Empiric antibiotic selection for adults</a>.)</span></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oral regimens</strong> – For most patients with skin abscess, oral antibiotic therapy is sufficient. We suggest <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, or <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We reserve <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> and other agents for patients who cannot take our preferred antibiotics. (See <a class="local">'Oral regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Parenteral regimens</strong> – Intravenous therapy is warranted for patients with signs of systemic toxicity, rapidly progressive or extensive erythema, or an inability to absorb oral therapy. We also suggest parenteral therapy in those who are immunosuppressed (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2">For these patients, we suggest <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients with sepsis or an immunocompromising condition, we combine vancomycin with <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> to provide a broader spectrum of coverage. (See <a class="local">'Parenteral regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Timing of antimicrobial administration</strong> – To optimize culture results, antibiotics are generally withheld prior to incision and drainage. However, for patients who have an indication for parenteral therapy or who have risk factors for endocarditis, administration prior to the procedure is appropriate. (See <a class="local">'Timing of antimicrobial administration'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of therapy</strong> – We suggest five to six days of therapy rather than longer (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Extended regimens (ie, up to 14 days) may be indicated for severe or slowly responding infections. Patients whose infection is complicated by <em>S. aureus</em> bacteremia typically require more intensive and longer durations, as discussed elsewhere. (See <a class="local">'Duration of antimicrobial therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">"Clinical approach to Staphylococcus aureus bacteremia in adults", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Special populations</strong> – Specific management considerations are warranted for patients with certain features including those with septic shock, immunosuppression, atypical sites of infection, infected wounds, or risk for endocarditis. (See <a class="local">'Special populations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring response</strong> – The goal of therapy is to achieve resolution of the abscess and surrounding cellulitis. Patients who undergo adequate incision and drainage typically have improvement in pain and size of the abscess shortly after the procedure. Surrounding erythema typically improves within 24 to 48 hours. (See <a class="local">'Monitoring response'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory infection</strong> – Imaging or re-exploration of the wound is indicated for refractory infections to ensure that further drainage is not necessary. Other less common causes of refractory infection include resistant organisms, inadequate tissue penetration of antibiotics, and incorrect diagnosis. (See <a class="local">'Refractory infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent infection</strong> – Causes of recurrences include suboptimal personal hygiene and interpersonal transmission. For patients with recurrent MRSA infection despite hygiene optimization or with ongoing transmission among close contacts, we suggest <em>S. aureus</em> decolonization (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Details regarding decolonization are found separately. (See <a class="local">'Recurrent infection'</a> above and  <a class="medical medical_review" href="/z/d/html/4048.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control", section on 'Decolonization'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a class="nounderline abstract_t">Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014; 59:147.</a></li><li><a class="nounderline abstract_t">Raff AB, Kroshinsky D. Cellulitis: A Review. JAMA 2016; 316:325.</a></li><li><a class="nounderline abstract_t">Fitch MT, Manthey DE, McGinnis HD, et al. Videos in clinical medicine. Abscess incision and drainage. N Engl J Med 2007; 357:e20.</a></li><li><a class="nounderline abstract_t">Miller LG, Quan C, Shay A, et al. A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. Clin Infect Dis 2007; 44:483.</a></li><li><a class="nounderline abstract_t">Gaspari RJ, Resop D, Mendoza M, et al. A randomized controlled trial of incision and drainage versus ultrasonographically guided needle aspiration for skin abscesses and the effect of methicillin-resistant Staphylococcus aureus. Ann Emerg Med 2011; 57:483.</a></li><li><a class="nounderline abstract_t">Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007; 51:4044.</a></li><li><a class="nounderline abstract_t">Duong M, Markwell S, Peter J, Barenkamp S. Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. Ann Emerg Med 2010; 55:401.</a></li><li><a class="nounderline abstract_t">Schmitz GR, Bruner D, Pitotti R, et al. Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection. Ann Emerg Med 2010; 56:283.</a></li><li><a class="nounderline abstract_t">Talan DA, Mower WR, Krishnadasan A, et al. Trimethoprim-Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess. N Engl J Med 2016; 374:823.</a></li><li><a class="nounderline abstract_t">Daum RS, Miller LG, Immergluck L, et al. A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. N Engl J Med 2017; 376:2545.</a></li><li><a class="nounderline abstract_t">Talan DA, Moran GJ, Krishnadasan A, et al. Subgroup Analysis of Antibiotic Treatment for Skin Abscesses. Ann Emerg Med 2018; 71:21.</a></li><li><a class="nounderline abstract_t">Gottlieb M, DeMott JM, Hallock M, Peksa GD. Systemic Antibiotics for the Treatment of Skin and Soft Tissue Abscesses: A Systematic Review and Meta-Analysis. Ann Emerg Med 2019; 73:8.</a></li><li><a class="nounderline abstract_t">Wang W, Chen W, Liu Y, et al. Antibiotics for uncomplicated skin abscesses: systematic review and network meta-analysis. BMJ Open 2018; 8:e020991.</a></li><li><a class="nounderline abstract_t">Duong M, Markwell S, Peter J, Barenkamp S. Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. Ann Emerg Med 2010; 55:401.</a></li><li><a class="nounderline abstract_t">Macfie J, Harvey J. The treatment of acute superficial abscesses: a prospective clinical trial. Br J Surg 1977; 64:264.</a></li><li><a class="nounderline abstract_t">Llera JL, Levy RC. Treatment of cutaneous abscess: a double-blind clinical study. Ann Emerg Med 1985; 14:15.</a></li><li><a class="nounderline abstract_t">Rutherford WH, Hart D, Calderwood JW, Merrett JD. Antibiotics in surgical treatment of septic lesions. Lancet 1970; 1:1077.</a></li><li><a class="nounderline abstract_t">Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010; 38:1045.</a></li><li><a class="nounderline abstract_t">Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589.</a></li><li><a class="nounderline abstract_t">Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 2014; 42:1749.</a></li><li><a class="nounderline abstract_t">Whiles BB, Deis AS, Simpson SQ. Increased Time to Initial Antimicrobial Administration Is Associated With Progression to Septic Shock in Severe Sepsis Patients. Crit Care Med 2017; 45:623.</a></li><li><a class="nounderline abstract_t">Liu VX, Fielding-Singh V, Greene JD, et al. The Timing of Early Antibiotics and Hospital Mortality in Sepsis. Am J Respir Crit Care Med 2017; 196:856.</a></li><li><a class="nounderline abstract_t">Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666.</a></li><li><a class="nounderline abstract_t">Vermandere M, Aertgeerts B, Agoritsas T, et al. Antibiotics after incision and drainage for uncomplicated skin abscesses: a clinical practice guideline. BMJ 2018; 360:k243.</a></li><li><a class="nounderline abstract_t">Harrington AT, Black JA, Clarridge JE 3rd. In Vitro Activity of Retapamulin and Antimicrobial Susceptibility Patterns in a Longitudinal Collection of Methicillin-Resistant Staphylococcus aureus Isolates from a Veterans Affairs Medical Center. Antimicrob Agents Chemother 2015; 60:1298.</a></li><li><a class="nounderline abstract_t">Al-Rawahi GN, Reynolds S, Porter SD, et al. Community-associated CMRSA-10 (USA-300) is the predominant strain among methicillin-resistant Staphylococcus aureus strains causing skin and soft tissue infections in patients presenting to the emergency department of a Canadian tertiary care hospital. J Emerg Med 2010; 38:6.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Healthcare-associated infections - Community Interface (HAIC): Emerging Infections Program (EIP) network report. Invasive Staphylococcus aureus, 2017. https://www.cdc.gov/hai/eip/pdf/2017-MRSA-Report-P.pdf (Accessed on May 04, 2022).</li><li><a class="nounderline abstract_t">Bobrow BJ, Pollack CV Jr, Gamble S, Seligson RA. Incision and drainage of cutaneous abscesses is not associated with bacteremia in afebrile adults. Ann Emerg Med 1997; 29:404.</a></li><li><a class="nounderline abstract_t">Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.</a></li></ol></div><div id="topicVersionRevision">Topic 138447 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24947530" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27434444" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cellulitis: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17989377" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Videos in clinical medicine. Abscess incision and drainage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17243049" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21239082" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A randomized controlled trial of incision and drainage versus ultrasonographically guided needle aspiration for skin abscesses and the effect of methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17846141" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19409657" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20346539" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus aureus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26962903" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Trimethoprim-Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28657870" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28987525" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Subgroup Analysis of Antibiotic Treatment for Skin Abscesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29530658" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Systemic Antibiotics for the Treatment of Skin and Soft Tissue Abscesses: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29437689" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Antibiotics for uncomplicated skin abscesses: systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19409657" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/322789" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The treatment of acute superficial abscesses: a prospective clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3880635" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Treatment of cutaneous abscess: a double-blind clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4191960" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Antibiotics in surgical treatment of septic lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20048677" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625125" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24717459" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28169944" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Increased Time to Initial Antimicrobial Administration Is Associated With Progression to Septic Shock in Severe Sepsis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28345952" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The Timing of Early Antibiotics and Hospital Mortality in Sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16914702" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Methicillin-resistant S. aureus infections among patients in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29437651" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Antibiotics after incision and drainage for uncomplicated skin abscesses: a clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26666950" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : In Vitro Activity of Retapamulin and Antimicrobial Susceptibility Patterns in a Longitudinal Collection of Methicillin-Resistant Staphylococcus aureus Isolates from a Veterans Affairs Medical Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18325716" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Community-associated CMRSA-10 (USA-300) is the predominant strain among methicillin-resistant Staphylococcus aureus strains causing skin and soft tissue infections in patients presenting to the emergency department of a Canadian tertiary care hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18325716" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Community-associated CMRSA-10 (USA-300) is the predominant strain among methicillin-resistant Staphylococcus aureus strains causing skin and soft tissue infections in patients presenting to the emergency department of a Canadian tertiary care hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9055782" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Incision and drainage of cutaneous abscesses is not associated with bacteremia in afebrile adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17446442" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
